-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Market Analysis] According to AstraZeneca's announcement in March, April 9, 2022 is the day when Zhu Tong, Vice President of AstraZeneca China and Head of Cardiovascular, Renal and Metabolism Division, officially ends
.
Not long ago, Lu Yanbin, deputy director of the strategic project management office of AstraZeneca's oncology business unit, also resigned due to personal reasons.
He was succeeded by Ms.
Yu Qiran, the current director of new product planning and marketing
.
According to incomplete statistics in the industry, within 10 months, AstraZeneca China has accumulated 10 senior executives who have "left", including the former AstraZeneca and the county team leader He Shuzhen, the former AstraZeneca China Oncology Yin Min, general manager of the business unit, Wang Dong, former vice president of AstraZeneca China and head of retail business department, Du Haochen, former vice president of AstraZeneca China and head of county business department, former AstraZeneca China digestive and respiratory atomization business Department (GNR) Assistant Vice President He Yimin, former AstraZeneca East RGM, Chairman of the Sales Advisory Committee Zhang Anwei, former AstraZeneca China Vice President, Head of Digital and Business Innovation Xu Jing, former AstraZeneca China Digestion and Entire Dong Lijun, general manager of product development business department,
etc.
So, what is the reason for the frequent departure of AstraZeneca China's executives? Many analysts believe that the change of executives of pharmaceutical companies is related to the adjustment of company structure and strategy under the changes in the pharmaceutical market
.
In the past 10 months when AstraZeneca China’s executives changed frequently, the company made several decisions to adjust its structure, such as merging the respiratory and autoimmune divisions, digestion and respiratory nebulization divisions, and establishing respiratory, digestive and autoimmune divisions.
Division, and terminated the divestiture of the Respiratory and Digestive Division; acquired Ruisong Pharmaceuticals, established the Rare Disease Division, and established the Omni-Channel Division, covering and county chronic disease business department, retail business department, community business department, Feiying business department And Dongwu County Market,
etc.
In addition, the performance of pharmaceutical companies may also affect the retention of executives
.
AstraZeneca’s financial report shows that in 2021, its revenue will be 37.
42 billion US dollars, an increase of nearly 10 billion US dollars over the previous year, but its revenue in China is not as good as before.
In the past, AstraZeneca’s revenue in China can achieve double-digit growth, but it will decline significantly in 2021.
.
From the perspective of the reasons, the main reason is that the new medical reform policies such as medical insurance negotiation and centralized procurement implemented in China in recent years have had an impact on the company's performance
.
It is reported that under the pressure of price reduction caused by medical insurance negotiations and centralized procurement, AstraZeneca China's growth will slow down in the second half of 2021, and revenue in the fourth quarter will decline by 4% year-on-year.
The continued impact of procurement and medical insurance may see a mid-single-digit decline in performance in China in 2022
.
It can be inferred that in the case of a slowdown in performance growth, the adjustment of pharmaceutical company personnel is passive and active
.
However, AstraZeneca is also prepared to take some measures to deal with the changing Chinese market environment
.
For example, in this year's adjustment, the spin-off of AstraZeneca and its county business has attracted much attention from the industry.
The company expressed its optimism about the county and grassroots markets in China, and plans to further expand the county market.
On the basis of the establishment of an omni-channel business unit, the company will use digitalization to help the grassroots.
of physicians improve their ability to treat specialties
.
At the same time, the launch of new products will be accelerated, and resources will be concentrated on centralized procurement and increased volume after entering medical insurance
.
In addition, with the rapid rise of domestic innovative pharmaceutical companies in recent years, AstraZeneca said that it is also optimistic about the merger and integration investment of innovative pharmaceutical companies
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Not long ago, Lu Yanbin, deputy director of the strategic project management office of AstraZeneca's oncology business unit, also resigned due to personal reasons.
He was succeeded by Ms.
Yu Qiran, the current director of new product planning and marketing
.
According to incomplete statistics in the industry, within 10 months, AstraZeneca China has accumulated 10 senior executives who have "left", including the former AstraZeneca and the county team leader He Shuzhen, the former AstraZeneca China Oncology Yin Min, general manager of the business unit, Wang Dong, former vice president of AstraZeneca China and head of retail business department, Du Haochen, former vice president of AstraZeneca China and head of county business department, former AstraZeneca China digestive and respiratory atomization business Department (GNR) Assistant Vice President He Yimin, former AstraZeneca East RGM, Chairman of the Sales Advisory Committee Zhang Anwei, former AstraZeneca China Vice President, Head of Digital and Business Innovation Xu Jing, former AstraZeneca China Digestion and Entire Dong Lijun, general manager of product development business department,
etc.
So, what is the reason for the frequent departure of AstraZeneca China's executives? Many analysts believe that the change of executives of pharmaceutical companies is related to the adjustment of company structure and strategy under the changes in the pharmaceutical market
.
In the past 10 months when AstraZeneca China’s executives changed frequently, the company made several decisions to adjust its structure, such as merging the respiratory and autoimmune divisions, digestion and respiratory nebulization divisions, and establishing respiratory, digestive and autoimmune divisions.
Division, and terminated the divestiture of the Respiratory and Digestive Division; acquired Ruisong Pharmaceuticals, established the Rare Disease Division, and established the Omni-Channel Division, covering and county chronic disease business department, retail business department, community business department, Feiying business department And Dongwu County Market,
etc.
In addition, the performance of pharmaceutical companies may also affect the retention of executives
.
AstraZeneca’s financial report shows that in 2021, its revenue will be 37.
42 billion US dollars, an increase of nearly 10 billion US dollars over the previous year, but its revenue in China is not as good as before.
In the past, AstraZeneca’s revenue in China can achieve double-digit growth, but it will decline significantly in 2021.
.
From the perspective of the reasons, the main reason is that the new medical reform policies such as medical insurance negotiation and centralized procurement implemented in China in recent years have had an impact on the company's performance
.
It is reported that under the pressure of price reduction caused by medical insurance negotiations and centralized procurement, AstraZeneca China's growth will slow down in the second half of 2021, and revenue in the fourth quarter will decline by 4% year-on-year.
The continued impact of procurement and medical insurance may see a mid-single-digit decline in performance in China in 2022
.
It can be inferred that in the case of a slowdown in performance growth, the adjustment of pharmaceutical company personnel is passive and active
.
However, AstraZeneca is also prepared to take some measures to deal with the changing Chinese market environment
.
For example, in this year's adjustment, the spin-off of AstraZeneca and its county business has attracted much attention from the industry.
The company expressed its optimism about the county and grassroots markets in China, and plans to further expand the county market.
On the basis of the establishment of an omni-channel business unit, the company will use digitalization to help the grassroots.
of physicians improve their ability to treat specialties
.
At the same time, the launch of new products will be accelerated, and resources will be concentrated on centralized procurement and increased volume after entering medical insurance
.
In addition, with the rapid rise of domestic innovative pharmaceutical companies in recent years, AstraZeneca said that it is also optimistic about the merger and integration investment of innovative pharmaceutical companies
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
